Ingo K. Mellinghoff, MD, FACP

Journal of Clinical Oncology
New York, United States

Ingo Mellinghoff, MD, FACP is Chair of the Neurology Department, Member in the Human Oncology and Pathogenesis Program, and incumbent Evnin Family Chair in Neuro-Oncology. He received his MD from the Technical University Munich School of Medicine and further training in oncology and molecular biology at the University of California, Los Angeles. Dr. Mellinghoff’s research has focused on the characterization of signaling pathways that are altered in primary brain tumors and on early phase clinical trials with novel drugs targeting these pathways. He is noted for his contributions to our understanding of growth factor receptors in glioblastoma, isocitrate dehydrogenase in low‐grade gliomas, and the B cell receptor signaling axis in central nervous system lymphoma. To accelerate and improve the evaluation of drug response in brain tumor patients, Dr. Mellinghoff more recently expanded his work to the development of new technologies to quantify deregulated cancer signaling, including sequencing of cell‐free DNA in cerebrospinal fluid, spatial mapping of cancer signaling pathways in tumor biopsies, and in‐vivo imaging approaches. Dr. Mellinghoff received the Sontag Foundation Distinguished Scientist Award, the Advanced Clinical Research Award in Glioma from the American Society of Clinical Oncology, and the Award for Excellence in Adult Clinical Research from the Society of Neuro‐Oncology. He is an elected member of the American Society of Clinical Investigators (ASCI) and the Association of American Physicians (AAP), Associate Editor for the Journal of Clinical Oncology, Scientific Editor for Cancer Discovery, and regular member of an NIH Study Section (Molecular Oncogenesis).